Compass Therapeutics (CMPX) Current Leases (2021 - 2026)

Compass Therapeutics (CMPX) has 6 years of Current Leases data on file, last reported at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 1159.63% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 1159.63% YoY), and the FY2025 full-year result was $1.0 million, up 195.86% from the prior year.
• Current Leases rose to $1.4 million in Q1 2026, from $1.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.4 million in Q1 2026 to a low of $109000.0 in Q1 2025.
• A 5-year average of $932352.9 and a median of $1.1 million in 2022 frame the typical range for Current Leases.
• Across the five-year window, Current Leases sank 91.09% in 2025 and soared 1159.63% in 2026, its largest moves.
• Tracing CMPX's Current Leases over 5 years: stood at $1.1 million in 2022, then grew by 9.12% to $1.2 million in 2023, then sank by 71.76% to $338000.0 in 2024, then jumped by 195.86% to $1.0 million in 2025, then surged by 37.3% to $1.4 million in 2026.
• Business Quant data shows CMPX's Current Leases at $1.4 million in Q1 2026, $1.0 million in Q4 2025, and $1.0 million in Q3 2025.